The Sprycel Market Size is valued at USD 5.47 Bn in 2022 and is predicted to reach USD 8.52 Bn by the year 2031 at a 5.2% CAGR during the forecast period for 2023-2031.
One of the effective cancer drugs is Sprycel. Adults with some significant forms of leukaemia (cancer of the white blood cells) are treated with it. Adult patients should use SPRYCEL® (dasatinib) for therapy. Newly discovered chronic myeloid leukaemia (CML) in the chronic phase that is Philadelphia chromosome-positive (Ph+) rapid, myeloid, lymphoid, or chronic blast phase Ph+ CML with intolerance or resistance to imatinib or earlier therapy.
SPRYCEL® is recommended for treating paediatric patients one year of age and older who have Ph+ ALL or acute lymphoblastic leukaemia with the Philadelphia chromosome. 'Chronic', 'accelerated', and 'blast' stages of CML. When alternative treatments, such as imatinib (another cancer medication), are ineffective or have unfavourable side effects, Sprycel is utilized.
Neutropenia, anaemia, and thrombocytopenia were the adverse events of Sprycel 100 mg once a day, which posed the most problems for the market. The hematologic adverse effects frequently start early in the course of therapy. Adverse non-hematological events typically manifest within the first two years of therapy.
According to the Phase I and II studies, headache, musculoskeletal pain, haemorrhage, infections, exhaustion, diarrhoea, pleural effusions, and nausea were the most frequent Non-hematological toxicities linked to the usage of Sprycel 100 mg once a day. Leukaemia and other blood-related diseases are becoming more common, awareness of treatment alternatives is developing, and major firms are investing more money in R&D efforts.
Competitive Landscape
Some Major Key Players In The Sprycel Market:
- Bristol-Myers Squibb (BMS)
- Novartis
- Teva Pharmaceutical Industries
- Mylan
- Accord Healthcare
- Sun Pharma
- Dr Reddy's Laboratories
- Aurobindo Pharma
Market Segmentation:
The sprycel market is segmented on the basis of demographic, psychographic, behavioural and medical. Based on demographics, the market is segmented as age, gender, and income. By psychographics, the market is segmented into lifestyle and attitudes. On the basis of behavioural, the market is segmented into usage rate, compliance, and treatment. As per the medical, the market is segmented into indication and disease stage.
Based On Psychographic, The Lifestyle Segment Is Accounted As A Major Contributor In The Sprycel Market
The lifestyle category is expected to hold a major share in the global sprycel market in 2022. This is attributed to changes in the lifestyle of the population in developing countries. Moreover, the high income of most of the population anticipated the use of branded drugs for severe diseases such as cancer for better treatment.
The Disease Stage Segment Witnessed Growth At A Rapid Rate
The disease stage segment is projected to grow at a rapid rate in the global Sprycel market owing to the increasing use of the Sprycel in Philadelphia chromosome–positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase (CP) treatment. Sprycel is used for adults with Ph+ CML who no longer respond well to conventional treatments, such as imatinib. Adults with Ph+ acute lymphoblastic leukaemia (Ph+ ALL) who no longer respond well to other treatments are treated by Sprycel, which is anticipated to push the market growth within the forecast period.
In The Region, The North American Sprycel Market Holds A Significant Revenue Share
The North American sprycel market is expected to record the highest market revenue share in the near future. The use of Sprycel has expanded significantly as a result of an increase in research on hereditary uncommon disorders, chronic myelogenous leukaemia (CML), acute lymphoblastic leukaemia (ALL), and other types of leukaemia, the presence of key players in the area, and government funding.
Sprycel Market Report Scope:
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 5.47 Bn |
|
Revenue Forecast In 2031 |
USD 8.52 Bn |
|
Growth Rate CAGR |
CAGR of 5.2% from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Demographic, Psychographc, Behavioral, Medical |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Bristol-Myers Squibb (BMS), Novartis, Teva Pharmaceutical Industries, Mylan, Accord Healthcare, Sun Pharma, Dr. Reddy's Laboratories, Aurobindo Pharma |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
